About Mylan
Mylan is a Healthcare company based in Canonsburg (United States) founded in 1954 by Milan Puskar and Don Panoz. Generic and specialty pharmaceuticals are manufactured and marketed globally. It operates on a Direct-to-Consumer (D2C) model. The company has 38,000 employees. Mylan has completed 6 acquisitions, including Cold-EEZE, DPT Laboratories and Famy Care. Its chief executive, as recorded, is Scott A Smith. Its website mylan.com draws about 26 thousand monthly visits. Mylan offers products and services including Medicines. Its focus areas include Pharmaceuticals and Generic Drugs. Its legal entity is Viatris.
Company details
Mylan, integrated into Viatris, is dedicated to enhancing access to quality medicines. The company operates within the global healthcare sector, aiming to empower individuals to live healthier lives at every stage. Solutions are provided to ensure patients receive necessary medications when and where needed.
- Latest Funding Round$589.35M (USD), Debt – Conventional
May 2018
- InvestorsDeutsche Bank
& 1 more
- Employee Count38,000
- Investments & AcquisitionsCold-EEZE
& 5 more
Products & Services of Mylan
Mylan offers a comprehensive portfolio of products and services, including Medicines.
Quality medicines are provided for global patient access.
Funding Insights of Mylan
- Total Rounds 5
- Last Round Debt – Conventional — $589.35M
- Investors Count 2
All 5 funding rounds of Mylan with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | $589.35M | Debt – Conventional | – | – | – |
| Jun 2016 | $6.5B | Debt – Conventional | – | – | – |
| Feb 2016 | $10.05B | Debt – Conventional | – | – | |
| Dec 2015 | $1B | Debt – Conventional | – | – | – |
| Jun 2015 | Post-IPO | – | – |
2 investors in total: 2 institutional.
Investors in Mylan
Mylan has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Deutsche Bank and Teva Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified banking and financial services are provided globally. | 1870 | db.com | Frankfurt Am Main, Germany | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | tevapharm.com | Petah Tikva, Israel |
Investor details for Mylan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mylan
704 people are tracked at Mylan (285 in leadership, 8 in board & advisors, 411 in team); the tracked headcount is 38,000.
| Name | Role | Group |
|---|---|---|
Milan Puskar | Co-Founder | Leadership |
Don Panoz | Co-Founder | Leadership |
Scott A Smith | CEO | Leadership |
Shawna Zoladz | Head Of Commercial Services, NA | Leadership |
Andrea Moore | Quality Director, Qp, RP | Leadership |
Claire Portefaix | Head Of Prescription Business Unit, Digital & Commercial Excellence | Leadership |
Patrick Schlebrowski | Head Of Business Unit Rx Promoted, Mylan Germany Gmbh (a Viatris Company) | Leadership |
Nuno Loureiro | Head Of Pharmacy Business Unit | Leadership |
Amanda Tolbert | Head Of Trade & Customs North America | Leadership |
Erika Maurer | HR Director Switzerland | Leadership |
Orla Fitzgerald | Head Of Digital Transformation & Commercial Excellence | Leadership |
Don Cornwell | Director | Leadership |
Tim Rouse | Director Respiratory R & D Project Leader | Leadership |
Tomasz Lorenz | Head Of Marketing Europe And Canada. (ad Interim) Head Of Marketing JANZ And Emerging Markets | Leadership |
Punyatoya Patnaik | Deputy General Manager | Leadership |
Michael Takla | Head Of Launch Excellence JANZ & Emerging Markets | Leadership |
Vincent Caron | Head Of Supply Chain & Operational Excellence | Leadership |
Darpan Chopra | General Manager Quality Control | Leadership |
Dan P. | Head Of Market Access And Value | Leadership |
Peter McCormick | Chief Supply Officer | Leadership |
684 more people are available in the full profile.
Complete people profiles for Mylan
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mylan
Mylan has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Cold-EEZE, DPT Laboratories and Famy Care.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Contract development and manufacturing services for pharmaceutical APIs are provided. | riemser.com | Greifswald, Germany | 2000 | Mar 2018 | •••• | |
Provider of lozenges and syrup for cough and cold | coldeeze.com | Morgantown, United States | 2000 | Jan 2017 | $50M | |
Pharmaceutical semi-solid and liquid dosage forms are developed and manufactured. | dptlabs.com | San Antonio, United States | 1938 | Jun 2016 | •••• | |
Online gaming and gambling platform | renaissanceah.com | Lake Forest, United States | 2010 | May 2016 | $950M | |
Laboratory focused on pharmaceutical | nostrumlabs.com | Kansas, United States | 1995 | May 2015 | $75M | |
Suite of women's health products like contraceptives, intrauterine devices, tubal rings and hormone-replacement therapy products | famycare.com | Mumbai, India | 1990 | Feb 2015 | $750M |
Complete acquisition details for Mylan
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Mylan
9 dated milestones of Mylan across 64 years, from founding to its latest funding, stage changes and deals.
- Founded Mylan is founded.
- Acquisition Acquires Famy Care.
- Acquisition Acquires Nostrum Laboratories.
- Funding First funding round.
- Acquisition Acquires Renaissance Acquisition Holdings.
- Acquisition Acquires DPT Laboratories.
- Acquisition Acquires Cold-EEZE.
- Acquisition Acquires RIEMSER Pharma.
- Funding Latest funding round, Debt – Conventional, of $589.4M.
Web traffic of Mylan
The website of Mylan (mylan.com) receives about 26.4K visits a month and ranks #1,585,141 among all websites worldwide, #2,132 in Biotechnology and Pharmaceuticals.
- Monthly visits26.4K
▲ 54.8% vs previous month
- Unique visitors7.8K
per month
- Global rank#1,585,141
among all websites
- Category rank#2,132
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit1.6
- Average visit47 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with Mylan. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pfizer.com | 100% | 1.9M | #24,984 | View details | |
watson.com | watson.com | 100% | #14,435,464 | – | |
| patheon.com | 82% | 89.1K | #488,648 | View details | |
| biovail.com | 82% | View details | |||
| myriad.com | 82% | 205.3K | #109,684 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 31 similar websites and full traffic analytics for Mylan
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 31 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Mylan (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | USD 3.02 B | 8,300 | ||
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | USD 5.1 B | 13,500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mylan
Complete news archive for Mylan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mylan
Mylan was founded in 1954 and raised its 1st funding round 61 years after it was founded.
Mylan is headquartered in Canonsburg, United States. It is registered at Canonsburg, Pennsylvania, United States.
Scott A Smith is the CEO of Mylan, as recorded in our data.
Mylan has 38,000 employees.
Mylan, integrated into Viatris, is dedicated to enhancing access to quality medicines. The company operates within the global healthcare sector, aiming to empower individuals to live healthier lives at every stage. Solutions are provided to ensure patients receive necessary medications when and where needed.
Mylan offers Medicines.
Mylan has made 6 acquisitions, including Cold-EEZE, DPT Laboratories, and Famy Care.
Mylan has 2 investors. Key investors include Deutsche Bank, and Teva Pharmaceuticals.
Mylan operates through Viatris.